

Sergey S Yakushin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1054259/sergey-s-yakushin-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

7 papers	821 citations	3 h-index	8 g-index
8 ext. papers	1,070 ext. citations	16.7 avg, IF	2.73 L-index

#	Paper	IF	Citations
7	Patients with a Combination of Atrial Fibrillation and Chronic Heart Failure in Clinical Practice: Comorbidities, Drug Treatment and Outcomes. <i>Rational Pharmacotherapy in Cardiology</i> , 2022 , 17, 816-824	0.5	1
6	Combination of Atrial Fibrillation and Coronary Heart Disease in Patients in Clinical Practice: Comorbidities, Pharmacotherapy and Outcomes (Data from the REKVAZA Registries). <i>Rational Pharmacotherapy in Cardiology</i> , 2021 , 17, 702-711	0.5	1
5	Early cardiovascular multimorbidity in out- and in-patient care: age characteristics and medication therapy (data from the REKVAZA and REKVAZA-CLINIC registries). <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2020 , 19, 2672	0.9	2
4	Young ambulatory patients with cardiovascular diseases: age and gender characteristics, comorbidity, medication and outcomes (according to RECVASA register). <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2019 , 18, 99-106	0.9	3
3	Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. <i>Lancet, The</i> , 2018 , 392, 2441-2451	40	161
2	Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2017 , 376, 652-662	59.2	427
1	Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. <i>Lancet, The</i> , 2017 , 390, 457-468	40	227